BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes.
Financial
VANTIS VASCULAR CLOSES $10M IN SERIES B-1 PREFERRED FINANCING
Funds will be used to initiate US commercialization of its CrossFAST™ Integrated Microcatheter Advanced Delivery System SAN JOSE, Calif., Dec. 12, 2024 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians with a passion to revolutionize…
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition.
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000 shares of its common stock (“Common Stock”) in the U.S. (the “Offering”). All shares of Common Stock to be sold in the Offering will […]
China’s NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP
– Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM –
The Society of Interventional Radiology announces its new chief executive officer
Eve Lee to join SIR on Jan. 27, 2025 FAIRFAX, Va., Dec. 5, 2024 /PRNewswire/ — The Society of Interventional Radiology (SIR) is pleased to announce that Eve Lee, MBA, CAE, will join the organization on Jan. 27, 2025, as its new chief executive officer. In this role, Ms. Lee will advance…
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
December 04, 2024 06:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its […]
Acutus Medical Announces Operational Downsizing
CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and operational downsizing.
Cleerly Raises $106 Million in Funding Led by Insight Partners to Revolutionize Heart Disease Care
December 4, 2024 (DENVER) – Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series C extension funding round, raising a total of $106 million. This funding round was led by global software investor Insight Partners and joined by Battery Ventures with participation from pre-existing investors. With this new funding, Cleerly will continue […]
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the completion of a $115 million Series D financing that included the conversion of issued convertible […]



